Surmodics, Inc. (NASDAQ:SRDX) Shares Purchased by Diametric Capital LP

Diametric Capital LP boosted its position in Surmodics, Inc. (NASDAQ:SRDX) by 89.6% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 20,437 shares of the company’s stock after buying an additional 9,659 shares during the period. Diametric Capital LP owned approximately 0.14% of Surmodics worth $809,000 as of its most recent SEC filing.

Other institutional investors also recently bought and sold shares of the company. Rhumbline Advisers boosted its holdings in shares of Surmodics by 4.4% in the fourth quarter. Rhumbline Advisers now owns 20,250 shares of the company’s stock valued at $802,000 after acquiring an additional 861 shares in the last quarter. Modus Advisors LLC acquired a new stake in Surmodics in the fourth quarter valued at about $40,000. SG Americas Securities LLC boosted its holdings in Surmodics by 22.1% in the 4th quarter. SG Americas Securities LLC now owns 6,940 shares of the company’s stock valued at $275,000 after purchasing an additional 1,255 shares in the last quarter. R Squared Ltd acquired a new position in Surmodics during the 4th quarter worth approximately $55,000. Finally, Charles Schwab Investment Management Inc. raised its stake in shares of Surmodics by 1.3% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 116,311 shares of the company’s stock worth $4,511,000 after buying an additional 1,491 shares in the last quarter. 96.63% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on the company. Needham & Company LLC restated a “hold” rating on shares of Surmodics in a research note on Thursday, January 30th. Lake Street Capital upgraded shares of Surmodics from a “hold” rating to a “buy” rating and set a $43.00 target price on the stock in a research report on Friday, March 7th. Finally, StockNews.com assumed coverage on shares of Surmodics in a research note on Monday, February 3rd. They set a “hold” rating on the stock. Four investment analysts have rated the stock with a hold rating and one has issued a buy rating to the stock. According to MarketBeat, Surmodics presently has an average rating of “Hold” and an average target price of $50.00.

Surmodics Stock Performance

SRDX opened at $30.53 on Tuesday. Surmodics, Inc. has a 1-year low of $25.17 and a 1-year high of $42.44. The stock has a market cap of $436.46 million, a P/E ratio of -30.23 and a beta of 1.19. The stock’s 50 day simple moving average is $32.74 and its 200 day simple moving average is $36.67. The company has a debt-to-equity ratio of 0.26, a current ratio of 5.45 and a quick ratio of 4.29.

Surmodics (NASDAQ:SRDX) last announced its quarterly earnings results on Thursday, February 6th. The company reported ($0.04) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.04. Surmodics had a negative return on equity of 4.39% and a negative net margin of 11.48%. As a group, equities analysts anticipate that Surmodics, Inc. will post 0.2 EPS for the current fiscal year.

Surmodics Profile

Surmodics, Inc, together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD).